Announced Wed, 29 Jul · 22:00 IST
Sun Pharma gets Brazil approval to market semaglutide for diabetes
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹1991.40
prior close
₹1993.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.7+0.6+0.6-0.3-2.3-1.4-2.6-2.0-2.4-4.5———
Up moveDown movePending
AI summary
Sun Pharma has received approval from Brazil's ANVISA to manufacture and market semaglutide injection for adults with type 2 diabetes. The drug will be launched in coming days via partner Hypera Pharma in two strengths (2 mg/1.5 mL and 4 mg/3 mL) as a once-weekly injectable pen. The semaglutide injectable market in Brazil is about USD 413 million.
Likely market impact
Opens a new market worth around USD 413 million and strengthens Sun Pharma's diabetes portfolio in Brazil and Latin America.